Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

The attorneys general sent a letter saying the FDA needs to take action because high demand for the weight loss drugs paired with shortages has created a market for counterfeits.

Novo Nordisk has reached an agreement to buy Germany ... which has been designed to halt and reverse this cardiac remodelling process. The drug is in the phase 2 HF-REVERT clinical trial ...